- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Genmab AS ADR (GMAB)
The Genmab AS ADR share price today is 37.07, view NASDAQ GMAB stock exchange data. Track the latest Genmab AS ADR share price with real-time updates on GMAB stock performance including market cap, day range, 52-week range and dividend yield. Access GMAB charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.33
37.15
52 wk Range
23.62
40.17
GMAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.3337.15
52 wk Range
23.6240.17
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GMAB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
44.13
Upside
+19.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Genmab AS receives Investment Bank Analyst Rating Update- Investing.com
Pro
Genmab AS receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 44.13
(+19.04% Upside)
Genmab AS ADR SWOT Analysis
Pipeline Potential | Genmab's diverse oncology pipeline, including promising candidates like Epkinly and Rina S., offers significant growth opportunities beyond Darzalex |
Financial Resilience | With a 96.1% gross profit margin and $13.82B market cap, Genmab demonstrates strong financial health amid strategic acquisitions and pipeline investments |
Market Challenges | Explore Genmab's strategies to navigate the competitive oncology landscape and reduce reliance on Darzalex as it approaches patent expiration in 2029 |
Analyst Perspectives | Price targets range from $46 to $48, with analysts seeing potential for over 100% upside if major pipeline successes materialize |
Genmab AS ADR Earnings Call Summary for Q2/2026
- Genmab raised FY 2026 revenue guidance to DKK 4.3-4.5B, up 19% YoY at midpoint; operating profit guidance lifted 7% to DKK 1.1-1.4B.
- H1 revenue rose 25% YoY driven by EPKINLY (up 48% YoY) and DARZALEX; proprietary portfolio sales jumped 37% to DKK 396M.
- Shares fell 1.88% to $28.71 despite raised guidance, as investors await key late-stage data readouts for EPKINLY, petosemtamab in Q4 2026-Q1 2027.
- Operating profit increased 18% in H1 while OpEx guidance rose only 2%, reflecting disciplined spending despite investments in phase III trials and launches.
- Management highlighted commercial momentum with EPKINLY expanding into community settings and 90%+ of key customers ordering for multiple sites.
Last Updated: 06-08-2026, 11:14 pm
Read Full TranscriptEarnings
Latest Release
06-08-2026
EPS / Forecast
0.49 / 0.34
Revenue / Forecast
1.16B / 1.1B
Compare GMAB to Peers and Sector
Metrics to compare | GMAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGMABPeersSector | |
|---|---|---|---|---|
P/E Ratio | 27.8x | 19.8x | −0.3x | |
PEG Ratio | −0.74 | −0.21 | 0.00 | |
Price/Book | 3.7x | 5.1x | 2.6x | |
Price / LTM Sales | 5.3x | 4.4x | 3.0x | |
Upside (Analyst Target) | 19.8% | 5.3% | 62.0% | |
Fair Value Upside | Unlock | 9.2% | 8.2% | Unlock |
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Genmab AS ADR (GMAB) Share Price Today?
The Genmab AS ADR share price today is 37.07.
What is the current Genmab AS ADR (GMAB) share price and day range?
As of 09-10-2026, the Genmab AS ADR share price is 37.07, with a previous close of 36.05. The share price has ranged from 36.33 to 37.15 today, while the 52-week range spans from 23.62 to 40.17.
What Is the Genmab AS ADR Market Cap?
As of today, Genmab AS ADR market cap is 21.90B.
What Is the Genmab AS ADR (GMAB) Share Price Target?
The average 12-month share price target for Genmab AS ADR is 44.13, with a high estimate of 58 and a low estimate of 33.5. 11 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +19.04% Upside potential.
What Is Genmab AS ADR's Earnings Per Share (TTM)?
The Genmab AS ADR EPS (TTM) is 12.65.
When Is the Next Genmab AS ADR Earnings Date?
Genmab AS ADR will release its next earnings report on 05-11-2026.
From a Technical Analysis Perspective, Is GMAB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Genmab AS ADR Trade On?
Genmab AS ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Genmab AS ADR?
The stock symbol for Genmab AS ADR is "GMAB."
How Many Times Has Genmab AS ADR Stock Split?
Genmab AS ADR has split 1 times.
How Many Employees Does Genmab AS ADR Have?
Genmab AS ADR has 3119 employees.
What Is the GMAB Premarket Price?
GMAB's last pre-market stock price is 36.50. The pre-market share volume is 4,100.00, and the stock has changed by 0.45, or 1.25%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.